Human cancer inhibitory pentapeptide heterocyclic and halophenyl

Details Human cancer inhibitory pentapeptide heterocyclic and halophenyl Human cancer inhibitory pentapeptide heterocyclic and halophenyl

1994-12-13

1997-09-02

Davenport, Avis M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530330, A61K 3800, C07K 500, C07K 700

Patent

active

056631499

ABSTRACT:
The synthesis and elucidation of nineteen heterocyclic or halophenyl amide erivatives of dolastatin 10 are disclosed. These compounds and the methods of producing those compounds offer demonstrated significant in vitro activity against several human cancer cell lines. These compounds and the methods of producing those compounds offer a commercially viable alternative to natural and synthetic dolastatin 10.

REFERENCES:
patent: 5410024 (1995-04-01), Pettit et al.
patent: 5502032 (1996-03-01), Haupt et al.
Pettit et al., J. Org. Chem. v. 59, pp. 2935-2938, 6287-6295, 1994.
Pettit et al., J. Org. Chem, v. 59, No. 7, pp. 1796-1800, 1994.
Pettit et al., Heterocycles, v. 39, No. 1, pp. 81-100, 1994.

Affiliated with

Also associated with

Rating

Human cancer inhibitory pentapeptide heterocyclic and halophenyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human cancer inhibitory pentapeptide heterocyclic and halophenyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cancer inhibitory pentapeptide heterocyclic and halophenyl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-308117